Zarxio (Filgrastim-sndz Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 2, 2017 Category: Drugs & Pharmacology Source Type: news
This Is What Obamacare's Critics Won't Admit Or Simply Don't Understand
THOUSAND OAKS, California ― Maryann Hammers is likely to die from ovarian cancer someday. But she hopes someday won’t come anytime soon.
Hammers, 61, received the diagnosis in late 2013, and doctors told her that it was stage 3-C, which meant that she could live for many years with the right treatment and a little luck. So far, she’s had both. She’s in remission for the second time, and her last course of chemotherapy ended a year and a half ago. But recent blood tests detected elevated levels of a protein associated with tumors, she explained when we met a few weeks ago. “Maybe it’s a fluk...
Source: Healthy Living - The Huffington Post - February 18, 2017 Category: Consumer Health News Source Type: news
Granix (Tbo-filgrastim Injection, for Subcutaneous Use) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 16, 2017 Category: Drugs & Pharmacology Source Type: news
Analyst: Insulet ’ s drug-delivery biz a long-term growth driver
Insulet’s (NSDQ:PODD) drug-delivery business will be a long-term growth driver for the company by as much as 20% a year for the next few years, according to Leerink Partners analysts.
Billerica, Mass.-based Insulet generates 86% of its revenue from its OmniPod insulin delivery device, according to Leerink. The OmniPod technology could be easily adapted to other drugs, according to the investment bank, which cited Insulet’s partnership with Amgen (NSDQ:AMGN) as a foundation for other wearable drug-delivery products.
“There are a significant number of injectable drugs that are nearing patent expiration over the nex...
Source: Mass Device - October 3, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Business/Financial News Drug-Device Combinations Amgen Insulet Corp. Leerink Partners Source Type: news
FDA Rejects Novartis Biosimilar App for Amgen Neulasta
The U.S. FDA has declined to approve Novartis' application for a biosimilar copy of Amgen's blockbuster, Neulasta. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - July 19, 2016 Category: Pharmaceuticals Source Type: news
FDA knocks back Novartis copy of Amgen's drug Neulasta
(Reuters) - U.S. regulators have declined to approve Novartis' so-called biosimilar copy of Amgen's Neulasta drug that fights infections in cancer patients, the Swiss drugmaker said on Tuesday. (Source: Reuters: Health)
Source: Reuters: Health - July 19, 2016 Category: Consumer Health News Tags: healthNews Source Type: news
Cinfa Biotech reports positive top-line clinical trial results of B12019 to treat neutropenia
Spanish biosimilars company Cinfa Biotech has reported positive top-line clinical trial results of B12019, a biosimilar version of Neulasta (pegfilgrastim), to treat chemotherapy-induced neutropenia. (Source: Drug Development Technology)
Source: Drug Development Technology - July 4, 2016 Category: Pharmaceuticals Source Type: news
Neulasta (Pegfilgrastim) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 9, 2016 Category: Drugs & Pharmacology Source Type: news
Neupogen® (Filgrastim): General Information for Clinicians
Centers for Disease Control and Prevention, National Center for Environmental Health. 12/10/2015This resource provides information about Neupogen (Filgrastim), which was approved in March 2015 by the U.S. Food and Drug Administration (FDA) to treat people who have received high doses of radiation. Neupogen is a drug that has been used successfully for cancer patients to produce more white blood cells. The fact sheet discusses who can take Neupogen, how it is given, and its side effects. (Text) (Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health)
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - April 28, 2016 Category: Global & Universal Authors: The U.S. National Library of Medicine Source Type: news
Use and Side Effects of Neulasta During Breast...
How is neulasta used during breast cancer chemotherapy, and what are some of its side effects and risks? (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - March 21, 2016 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news
Zarxio (Filgrastim-sndz Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 16, 2016 Category: Drugs & Pharmacology Source Type: news
What is the Difference Between Neulasta and...
Neutropenia during chemotherapy is treated with Neulasta or Neupogen. What's the difference, why is each chosen and what are the costs? (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - March 16, 2016 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news
EU agency accepts Sandoz application for pegfilgrastim biosimilar
ZURICH (Reuters) - The European Medicines Agency (EMA) has accepted an application to review Sandoz's biosimilar to Amgen's EU-licensed Neulasta (pegfilgrastim), a recombinant human granulocyte colony-stimulating factor, Sandoz parent Novartis said on Thursday. (Source: Reuters: Health)
Source: Reuters: Health - February 11, 2016 Category: Consumer Health News Tags: healthNews Source Type: news
Novartis: Study shows copycat works just as well as Amgen drug
ZURICH (Reuters) - Novartis's copycat version of Amgen's Neulasta worked just as well as the original drug in preventing a condition that can lead to infections among breast cancer sufferers, the Swiss company said in a statement on Monday. (Source: Reuters: Health)
Source: Reuters: Health - December 7, 2015 Category: Consumer Health News Tags: healthNews Source Type: news
